A pharmaceutical composition for inhibiting cancer metastasis using regulation of BIGH3

Item Number:	548
Industry:	Therapeutic
Category:	Oncology
Development Stage:	Early Stage
Organisation Type:	University
Country:	South Korea
Business Opportunity:	Out-Licensing, Technology Transfer, Collaboration R&D

DESCRIPTION

We report that lithium inhibits colon cancer metastasis by blocking lymphangiogenesis. Lithium reduces the expression of transforming growth factor-β-induced protein (TGFBIp) in colon cancer cells by inhibiting Smad3 phosphorylation via GSK3β inactivation. Moreover, lithium inhibits lymphatic endothelial cell migration, which is increased upon TGFBIp expression in tumor cells.

Features & Contact

List new technologies or browse our website with full access

CLICK HERE TO START

All
Biomedical
DDS
Diagnostic
Mechanism
Medical Device
Platform
Research
Therapeutic
Various/Other

All
Analgesia / Anaesthesia
Animal Health
Anti-Aging
Antibody
Bioinformatics / Software
Biomaterial
Bioprocessing
Bone / Joint / Connective Tissue
Cardiovascular / Haematology
Cell Therapy
Cellular Analysis
DDS
Dermatology
Diabetes
Diagnostic / Imaging
Digital Health
Drug Discovery / Screening
Endocrinology / Cytokines
Endoscopy
Fibrosis
Gastroenterology
Gene Therapy
Hospital & Surgery
Immunology
Infectious Disease
Inflammation
Liver Disease
Metabolism / Obesity
Neuroscience / Neurology
Nutraceuticals / Phytotherapeutics
Oncology
Ophthalmology
Oral Health
Orthopaedic
Otolaryngology
Paediatrics
Platform
Proteomics / Genomics
Reproduction
Respiratory Disease
Stem Cells
Tissue Engineering
Urology / Renal / Urogenital
Vaccine
Women's Health
Wound Healing

All
Research
Early Stage
Preclinical
Clinical Trials - Phase 1
Clinical Trials - Phase 2
Clinical Trials - Phase 3
Preregistration
Registered / Finished Product
Prototype

All
Charity
Private Corporation
Government Institute
Private Institute
University
Startup
Venture Capital
Consultancy